YARTEMLEA
LaunchmAbnarsoplimab
BLAINTRAVENOUSINJECTIONPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YARTEMLEA (narsoplimab) is an intravenous monoclonal antibody approved in December 2025 for COVID-19. The mechanism of action and specific target are not disclosed in available data. Patients with severe or critical COVID-19 are the target population.
Growth
Early-stage launch with minimal current market penetration; commercial team expansion likely as hospital adoption ramps and reimbursement landscapes stabilize.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YARTEMLEA is a newly launched IV monoclonal antibody with zero linked job openings and an unproven market position in a saturated COVID-19 indication. Career opportunity is highest in early-stage commercial roles (brand management, field MSL, specialty sales) where you would help establish market presence; stability is unclear given competitive pressure and unknown patent protection.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.